Adaptive Biotechnologies logo

ADPT - Adaptive Biotechnologies Share Price

$38.7 -0.2  -0.6%

Last Trade - 29/05/20

Sector
Healthcare
Size
Large Cap
Market Cap £3.98bn
Enterprise Value £3.53bn
Revenue £75.6m
Position in Universe 1067th / 6364
Bullish
Bearish
Unlock ADPT Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Adaptive Biotechnologies Corp revenues increased 65% to $20.9M. Net loss applicable to common stockholders increased 68% to $31.4M. Revenues reflect Development revenue segment increase of 74% to $11.4M, Sequencing revenue segment increase of 56% to $9.5M. Higher net loss reflects General and administrative - Balancing increase of 69% to $10M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ADPT Revenue Unlock ADPT Revenue

Net Income

ADPT Net Income Unlock ADPT Revenue

Normalised EPS

ADPT Normalised EPS Unlock ADPT Revenue

PE Ratio Range

ADPT PE Ratio Range Unlock ADPT Revenue

Dividend Yield Range

ADPT Dividend Yield Range Unlock ADPT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ADPT EPS Forecasts Unlock ADPT Revenue
Profile Summary

Adaptive Biotechnologies Corp is a biotechnology company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform generates clinical immunomics data to decode the adaptive immune system. Its products and pipeline includes immunoSEQ, clonoSEQ and cellular therapy. It offers its immunoSEQ technology as a service and a kit. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). clonoSEQ is its diagnostic test product for the detection and next-generation sequencing (NGS)-based monitoring of minimal residual disease (MRD) in bone marrow samples in patients with myeloma (MM) and acute lymphoblastic leukemia (ALL). clonoSEQ is designed to sequence all rearranged receptor sequences in a tumor in parallel to enable MRD monitoring. It also focuses on developing immune-mediated therapies in oncology and other disease areas.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated September 8, 2009
Public Since June 27, 2019
No. of Shareholders: 216
No. of Employees: 453
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 126,887,606
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ADPT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ADPT
Upcoming Events for ADPT
Friday 12th June, 2020
Adaptive Biotechnologies Corp Annual Shareholders Meeting
Monday 10th August, 2020 Estimate
Q2 2020 Adaptive Biotechnologies Corp Earnings Release
Tuesday 10th November, 2020 Estimate
Q3 2020 Adaptive Biotechnologies Corp Earnings Release
Frequently Asked Questions for Adaptive Biotechnologies
What is the Adaptive Biotechnologies share price?

As of 29/05/20, shares in Adaptive Biotechnologies are trading at $38.7, giving the company a market capitalisation of £3.98bn. This share price information is delayed by 15 minutes.

How has the Adaptive Biotechnologies share price performed this year?

Shares in Adaptive Biotechnologies are currently trading at $38.7 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Adaptive Biotechnologies price has moved by % over the past year.

What are the analyst and broker recommendations for Adaptive Biotechnologies?

There are no analysts currently covering Adaptive Biotechnologies.

When will Adaptive Biotechnologies next release its financial results?

Adaptive Biotechnologies is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Adaptive Biotechnologies dividend yield?

Adaptive Biotechnologies does not currently pay a dividend.

Does Adaptive Biotechnologies pay a dividend?

Adaptive Biotechnologies does not currently pay a dividend.

When does Adaptive Biotechnologies next pay dividends?

Adaptive Biotechnologies does not currently pay a dividend.

How do I buy Adaptive Biotechnologies shares?

To buy shares in Adaptive Biotechnologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Adaptive Biotechnologies?

Shares in Adaptive Biotechnologies are currently trading at $38.7, giving the company a market capitalisation of £3.98bn.

Where are Adaptive Biotechnologies shares listed? Where are Adaptive Biotechnologies shares listed?

Here are the trading details for Adaptive Biotechnologies:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ADPT
What kind of share is Adaptive Biotechnologies?

Based on an overall assessment of its quality, value and momentum, Adaptive Biotechnologies is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Adaptive Biotechnologies share price forecast 2020?

Shares in Adaptive Biotechnologies are currently priced at $38.7. At that level they are trading at 15.63% discount to the analyst consensus target price of 0.00.

Analysts covering Adaptive Biotechnologies currently have a consensus Earnings Per Share (EPS) forecast of -0.893 for the next financial year.

How can I tell whether the Adaptive Biotechnologies share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adaptive Biotechnologies. Over the past six months, the relative strength of its shares against the market has been 46.28%. At the current price of $38.7, shares in Adaptive Biotechnologies are trading at 22.5% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Adaptive Biotechnologies PE Ratio?

We were not able to find PE ratio data for Adaptive Biotechnologies.

Who are the key directors of Adaptive Biotechnologies?

Adaptive Biotechnologies's management team is headed by:

Chad Robins - CHM
Harlan Robins - CFD
Nancy Hill - SVP
Julie Rubinstein - PRE
Chad Cohen - CFO
Francis Lo - CHO
Sharon Benzeno - SVP
Charles Snag - SVP
Peter Neupert - LED
Kevin Conroy - IND
Eric Dobmeier - IND
David Goel - IND
Michelle Griffin - IND
Stacy Taylor - SVP
Jyoti Palaniappan - SVP
Who are the major shareholders of Adaptive Biotechnologies?

Here are the top five shareholders of Adaptive Biotechnologies based on the size of their shareholding:

Viking Global Investors LP Hedge Fund
Percentage owned: 26.4% (33.5m shares)
Matrix Capital Management Company, LP Investment Advisor/Hedge Fund
Percentage owned: 11.91% (15.1m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 3.52% (4.47m shares)
Senator Investment Group LP Hedge Fund
Percentage owned: 2.67% (3.39m shares)
Zoltners (Andris A) Individual Investor
Percentage owned: 2.62% (3.32m shares)
Similar to ADPT
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.